Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)13.25
  • Today's Change0.12 / 0.91%
  • Shares traded1.86k
  • 1 Year change+41.26%
  • Beta0.9559
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,0781,338790
Total Receivables, Net3,7003,8154,266
Total Inventory3,4703,5203,978
Prepaid expenses1,565195257
Other current assets, total3,1631,7691,612
Total current assets12,97610,63510,903
Property, plant & equipment, net3,0053,2843,479
Goodwill, net9,86710,42612,114
Intangibles, net19,18122,60726,134
Long term investments166940
Note receivable - long term------
Other long term assets1,7972,050880
Total assets47,68650,02254,843
LIABILITIES
Accounts payable1,3811,1581,056
Accrued expenses2,2712,1893,226
Notes payable/short-term debt001,493
Current portion long-term debt/capital leases1,9431,2511,860
Other current liabilities, total2,1822,1492,249
Total current liabilities7,7776,7469,884
Total long term debt16,18818,01519,717
Total debt18,13219,26623,070
Deferred income tax1,7362,4322,815
Minority interest------
Other liabilities, total1,5171,7571,934
Total liabilities27,21828,95034,350
SHAREHOLDERS EQUITY
Common stock121212
Additional paid-in capital18,81518,64618,536
Retained earnings (accumulated deficit)4,6405,1763,689
Treasury stock - common(252)----
Unrealized gain (loss)(1.2)(2.3)0
Other equity, total(2746)(2759)(1744)
Total equity20,46721,07220,493
Total liabilities & shareholders' equity47,68650,02254,843
Total common shares outstanding1,2011,2141,210
Treasury shares - common primary issue2100
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.